Journals
Publish with us
Publishing partnerships
About us
Blog
Disease Markers
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Disease Markers
/
2018
/
Article
/
Tab 4
/
Research Article
IgG Antibodies to GlcNAc
β
and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment
Table 4
Diagnostic parameters of patients in stage F0 vs. F1–4.
Parameter
Genotype
Cut-off
Sensitivity
95% CI
Specificity
95% CI
Anti-GlcNAc
β
1b
0.334
0.59
0.39–0.78
0.84
0.64–0.95
ALP
1b
74.5
0.64
0.41–0.83
0.76
0.50–0.93
1b and 3a
72.5
0.64
0.45–0.80
0.77
0.56–0.91